The primary efficacy objective was to determine whether asundexian is at least noninferior to apixaban for the prevention of stroke or systemic embolism. The primary safety objective was to ...

In the OCEANIC-AF trial, asundexian was found to be inferior to apixaban for stroke prevention in patients with a high risk ...

Asundexian 50 mg daily was inferior to apixaban for stroke and systemic embolism prevention in high-risk patients with atrial fibrillation (AF), according to late-breaking research presented in a ...

According to US secondary stroke prevention guidelines, patients with ESUS should not be treated with anticoagulants or ...

London, United Kingdom – 1 September 2024: Asundexian 50 mg daily was inferior to apixaban for stroke and systemic embolism prevention in high-risk patients with atrial fibrillation (AF ...

Asundexian 50 mg daily was inferior to apixaban for stroke and systemic embolism prevention in high-risk patients with atrial fibrillation (AF), according to late-breaking research presented in a ...

Ami Organics’ strength in R&D and manufacturing large-scale pharma intermediates will help it increase the contract revenue ...

Antiplatelets are particularly beneficial for people who have had a previous heart attack or stroke, those with CAD, or ...

Purpose The pharmacology, pharmacokinetics, efficacy, and safety of apixaban are reviewed. Summary Apixaban is an oral, direct, selective factor Xa inhibitor with a rapid onset of action.

Since herbal supplements are often marketed as natural remedies for a variety of health conditions, many people mistakenly ...

Researchers used real-world clinical data to attempt to emulate a randomized controlled trial testing the effectiveness of two blood thinners, apixaban and warfarin, to prevent stroke in patients ...